Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Jamie Powers

Nurse Practitioner, Gerontology Bowling Green, KY Nurse Practitioner

NPI 1790246130 CMS profile 10462979

484 Golden Autumn Way Ste 201, Bowling Green, KY 42103

Open in the dashboard

General payments

$3,146

205 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jamie Powers of Bowling Green, KY is reported in the CMS Open Payments database as having received $3,146 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $190 12
2023 General $236 19
2022 General $2,066 129
2021 General $655 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Powers
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Jamie Powers were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Jamie Powers Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $655 $133 $44–$396 $132
2022 $2,066 $142 $48–$452 $149
2023 $236 $158 $53–$482 $160
2024 $190 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $1,382 93 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $543 41 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $207 13 payments
  4. Gilead Sciences, Inc. $157 10 payments
  5. Intercept Pharmaceuticals, Inc. $90 6 payments
  6. Celgene Corporation $88 6 payments
  7. Nestle HealthCare Nutrition Inc. $83 4 payments
  8. Janssen Scientific Affairs, LLC $81 1 payment
  9. Janssen Biotech, Inc. $81 4 payments
  10. QOL Medical, LLC $64 4 payments
  11. Other $371 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $3,146 205 payments
Products named General payments · program years 2021–2024
  1. RINVOQ $419 27 payments
  2. CREON $335 24 payments
  3. LINZESS $330 24 payments
  4. XIFAXAN $308 28 payments
  5. SKYRIZI $294 17 payments
  6. TRULANCE $235 13 payments
  7. MAVYRET $216 16 payments
  8. HUMIRA $213 14 payments
  9. ENTYVIO $168 10 payments
  10. STELARA $162 5 payments
  11. Other $1,007 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record